Wanbury Limited has received GMP compliance certification from the Australian Therapeutic Goods Administration (TGA) for its Tanuku manufacturing site. The approval covers six key APIs, including Metformin and Tramadol, clearing the path for the company to begin exports to the Australian market. This regulatory validation bolsters the firm's presence in international markets and highlights its focus on high-quality manufacturing standards.
Wanbury Receives Australian TGA GMP Approval for Tanuku Facility
Facility: Tanuku, Andhra Pradesh | Certification: TGA GMP Compliance
Reader Takeaway: TGA approval validates manufacturing standards and unlocks export potential for six APIs in Australia.
What just happened
Wanbury Limited has been granted a Good Manufacturing Practice (GMP) compliance certificate by Australia's Therapeutic Goods Administration (TGA). This follows an inspection conducted at the company's manufacturing facility in Tanuku, Andhra Pradesh, on June 8–9, 2026. The certificate is valid until December 9, 2028, and confirms the site meets the PIC/S Guide to Good Manufacturing Practice for medicinal products.
Why this matters
This regulatory clearance is a significant step in Wanbury’s strategy to expand into highly regulated international markets. With the TGA stamp of approval, the company can now proceed with the necessary regulatory filings to begin supplying six specific Active Pharmaceutical Ingredients (APIs) to the Australian market. These products include Metformin Hydrochloride, Tramadol Hydrochloride, Sertraline Hydrochloride, Diphenhydramine Hydrochloride, Mefenamic Acid, and Paroxetine Hydrochloride Hemihydrate.
The backstory
The inspection process, which culminated in the certification effective October 28, 2026, reflects the company's efforts to align its manufacturing processes with international quality benchmarks. By successfully navigating the scrutiny of a major health regulator like the Australian TGA, Wanbury enhances its credibility with global pharmaceutical partners and sponsors.
What to track next
Investors should monitor future disclosures regarding the actual commencement of supply contracts to Australian sponsors. While the certification is a major operational milestone, the financial impact will depend on the speed at which the company converts this regulatory clearance into export revenue and the volume of orders secured in the Australian territory.